Mayo Clinic Proceedings - Symposium on Neoplastic Hematology and Medical Oncology - Advances in the Treatment of Metastatic Prostate Cancer
One of the premier peer-reviewed clinical journals in general and internal medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 125,000. Mayo Clinic Proceedings is published by Elsevier and sponsored by Mayo Clinic and the Mayo Foundation for Medical Education and Research. The mission of Mayo Clinic Proceedings is to promote the best interest of patients by advancing the knowledge and professionalism of the physician community. Since 2009 the Journal has offered CME credit for specific articles from both the Mayo Clinic for Concise Review for Clinicians and specially commissioned Symposia articles (comprehensive coverage on one topic).
Participation in this activity consists of reviewing articles and responding to a short online test. It is estimated that this activity will take approximately one hour per article. There is no charge for participating in this Journal CME activity.
NOTE: You must select AMA PRA Category 1 CreditTM in your profile's credit eligiblility field in order for the sytem to recognize that you want CME credit. The system will only issue credit for the credit types that match your profile.
To receive CME credit, please do the following:
- Click Take Course
- Complete quiz and evaluation (There is a required 80% pass rate in order to earn credit, with 1 retake allowed.)
- Print your Record of Attendance
Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Mayo Clinic College of Medicine designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
William Lanier, M.D., Thomas Beckman, M.D., Christopher M. Wittich, M.D., Terry Jopke, Nicki Smith
Jong Chul Park, MD, Senior Clinical Associate, Genito-Urinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University
Mario A. Eisenberger, MD, R. Dale Hughes Professor of Oncology And Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University
The planning committee listed above have no financial relationships to disclose.
The authors, Jong Chul Park, MD and Mario A. Eisenberger, MD have no financial relationships to disclose.
References to off-label and/or investigational usage(s) of pharmaceuticals or instruments:
Manufacturer(s)/Provider(s): Bristol Myers Squibb, Genentech, Bavarian Nordik
Product(s)/Device(s): Prostvac, Ipililumab, Pembrolizumab
The target audience for Mayo Clinic Proceedings is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research.
On completion of this article, you should be able to (1) describe and discuss the various clinical paradigms of advanced prostate cancer, (2) describe and discuss current treatments for patients with metastatic prostate cancer, and (3) discuss future directions of research in metastatic prostate cancer.
- 1.00 AMA PRA Category 1 Credit™